Cardiome Pharma Gets Approval For BRINAVESS In South Africa - Quick Facts

(RTTNews) - Cardiome Pharma Corp. (CRME, COM.TO), a biopharmaceutical company, announced the approval of BRINAVESS in South Africa by the Medicines Control Council or MCC for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The MCC oversees the regulation of medicines in South Africa.

Karim Lalji, Cardiome's Chief Commercial Officer, noted, "We are committed to partnering BRINAVESS in this important pharmaceutical market as we continue to focus Cardiome's direct sales efforts on key countries in Europe."

According to research conducted by IMS Health, South Africa is one of the largest countries in Africa in terms of established pharmaceutical markets with total pharmaceutical sales reaching $3.7B in 2011.